Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease

NCT: NCT05064514 · ACTIVE_NOT_RECRUITING

NCT IDNCT05064514
StatusACTIVE_NOT_RECRUITING
Start Date2022-04-06
Completion2028-05-21

Brief Summary

The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.

Frequently Asked Questions

What is Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease?

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease is a clinical trial registered under NCT05064514. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05064514?

The current status of NCT05064514 (Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease) is: ACTIVE_NOT_RECRUITING.

When did Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease start?

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease started on 2022-04-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑